BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16374120)

  • 21. FDG-PET/CT of Vulvar Adenocarcinoma With Diffuse Metastases.
    Patel D; Anderson TM; Lu Y
    Clin Nucl Med; 2016 Sep; 41(9):710-1. PubMed ID: 27187733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDG-PET imaging in duodenal cancer.
    Watanabe N; Hayashi S; Kato H; Shimizu M; Kamisaki Y; Noguchi K; Kishida M; Matsunari I; Hisada K; Seto H
    Ann Nucl Med; 2004 Jun; 18(4):351-3. PubMed ID: 15359930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer.
    Ito S; Kato K; Ikeda M; Iwano S; Makino N; Tadokoro M; Abe S; Nakano S; Nishino M; Ishigaki T; Naganawa S
    J Nucl Med; 2007 Jun; 48(6):889-95. PubMed ID: 17504877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
    Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M
    Haematologica; 2007 Jan; 92(1):50-5. PubMed ID: 17229635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can whole-body MRI replace (18)F-fluorodeoxyglucose PET/CT?
    Kwee TC
    Lancet Oncol; 2014 Mar; 15(3):243-4. PubMed ID: 24559804
    [No Abstract]   [Full Text] [Related]  

  • 27. The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging.
    Mittal BR; Manohar K; Kashyap R; Bhattacharya A; Singh B; Singh G
    Hell J Nucl Med; 2011; 14(2):135-9. PubMed ID: 21761015
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Ozguven S; Kesim S; Oksuzoglu K; Dane F; Ones T; Erdil TY
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):39-40. PubMed ID: 31594699
    [No Abstract]   [Full Text] [Related]  

  • 29. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncocytoma of the parotid gland: a potential false-positive finding on 18F-FDG PET.
    Shah VN; Branstetter BF
    AJR Am J Roentgenol; 2007 Oct; 189(4):W212-4. PubMed ID: 17885033
    [No Abstract]   [Full Text] [Related]  

  • 31. [Malignant tumor with false negative 18F-FDG PET image].
    Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness and pitfalls of F-18-FDG PET/CT for diagnosing extramedullary acute leukemia.
    Zhou WL; Wu HB; Wang LJ; Tian Y; Dong Y; Wang QS
    Eur J Radiol; 2016 Jan; 85(1):205-210. PubMed ID: 26724667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Extension study and evaluation of the therapeutic response in a patient with metastatic lung adenocarcinoma using sequential study with ¹⁸F-FDG PET-CT and ¹⁸F-fluoride PET-CT].
    Moragas M; Soler M; Riera E; García JR
    Rev Esp Med Nucl Imagen Mol; 2015; 34(1):45-8. PubMed ID: 24690280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benign bone cyst mimicking skeletal metastasis on (18)F-FDG-PET.
    Khurana A; Jaimini A; Tripathi M; Mondal A
    Hell J Nucl Med; 2009; 12(2):179-80. PubMed ID: 19675880
    [No Abstract]   [Full Text] [Related]  

  • 35. F-18 FDG PET/CT can help differentiate SAPHO syndrome from suspected metastatic bone disease.
    Patel CN; Smith JT; Rankine JJ; Scarsbrook AF
    Clin Nucl Med; 2009 Apr; 34(4):254-7. PubMed ID: 19300064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Utility of PET-18FDG in primary tumor site in a patient with cerebral metastases].
    Suárez Fernández JP; Serna Macías JA; Domínguez Grande ML; Liaño H; Pozo MA; Maldonado Suárez A
    Rev Esp Med Nucl; 2005; 24(4):253. PubMed ID: 16122410
    [No Abstract]   [Full Text] [Related]  

  • 37. Adenomyomatosis of the gallbladder: another cause for a "hot" gallbladder on 18F-FDG PET.
    Maldjian PD; Ghesani N; Ahmed S; Liu Y
    AJR Am J Roentgenol; 2007 Jul; 189(1):W36-8. PubMed ID: 17579133
    [No Abstract]   [Full Text] [Related]  

  • 38. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
    Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
    Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U; Even-Sapir E
    Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?
    Vargas HA; Martin-Malburet AG; Takeda T; Corradi RB; Eastham J; Wibmer A; Sala E; Zelefsky MJ; Weber WA; Hricak H
    Urol Oncol; 2016 Nov; 34(11):482.e5-482.e10. PubMed ID: 27346339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.